SCHEMBL1494945

SCHEMBL1494945

CN1CCc2c(sc(NC(=O)C3CCCCC3)c2-c2nc3ccccc3s2)C1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 10/20 0.80
KDM4E B2RXH2 3/20 0.73
TP53 P04637 2/20 0.73
MEN1 O00255 2/20 0.73
HTT P42858 2/20 0.73
KMT2A Q03164 2/20 0.73
ALDH1A1 P00352 2/20 0.73
MAPT P10636 2/20 0.73
HPGD P15428 1/20 0.73
TSHR P16473 1/20 0.73
UHRF1 Q96T88 1/20 0.67
LMNA P02545 3/20 0.66
RXFP1 Q9HBX9 1/20 0.62
MYC P01106 1/20 0.59
NPC1 O15118 2/20 0.58
USP2 O75604 2/20 0.58
POLB P06746 1/20 0.58
RECQL P46063 1/20 0.58
RAB9A P51151 1/20 0.58
BLM P54132 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1495045 0.95 KDM4E (0.80) APEX1KDM4ETP53MEN1HTT
Hydrochloric Acid SCHEMBL14777452 0.95 KDM4E (0.79) APEX1KDM4ETP53MEN1HTT
SCHEMBL1494678 0.90 MAPT (0.92) APEX1KDM4ETP53MEN1HTT
SCHEMBL4727217 0.89 APEX1 (0.74) APEX1KDM4ETP53MEN1HTT
SCHEMBL3752307 0.89 APEX1 (1.00) APEX1KDM4ETP53MEN1HTT
SCHEMBL13832369 0.88 APEX1 (0.98) APEX1KDM4ETP53MEN1HTT
SCHEMBL13735042 0.86 APEX1 (1.00) APEX1KDM4ETP53MEN1HTT
SCHEMBL13832370 0.84 APEX1 (0.92) APEX1KDM4ETP53MEN1HTT
SCHEMBL13833677 0.84 KDM4E (0.76) APEX1KDM4ETP53MEN1HTT
SCHEMBL1495006 0.83 APEX1 (0.80) APEX1KDM4ETP53MEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053915-A1 HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM ALLA CHEM, LLC (US) 2011-03-03 US claimed
US-8486945-B2 Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system Ivachtchenko, Alexandre Vasilievich (US) 2013-07-16 US disclosed
US-20110053915-A1 HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM ALLA CHEM, LLC (US) 2011-03-03 US disclosed
US-20110053915-A1 HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM ALLA CHEM, LLC (US) 2011-03-03 US disclosed
WO-2009077956-A2 HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM ALLA CHEM, LLC (US) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053915-A1 HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM SHH, SMO, GLI1 APEX1 4588/4885KDM4E 2294/4885TP53 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.